Alnylam (ALNY) | Stock Overview & Key Data

Alnylam Pharmaceuticals Inc. | Large-cap | Healthcare

$308.87

0.29%

| Alnylam Stock Comparison:

Alnylam vs Vertex Alnylam vs Regeneron Alnylam vs Royalty Pharma plc Alnylam vs Insmed Alnylam vs Incyte Alnylam vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Alnylam Performance Comparison

Loading chart data...

Alnylam

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $302.32 High: $309.63

on June 16, 2025

52 Week Range

Low: $152.30 High: $310.22

on June 18, 2024

on June 6, 2025

All-Time High: $310.22 on June 6, 2025

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $40.2B

EPS i -2.10

P/E Ratio (TTM) i N/A

Forward P/E i -252.45

P/B Ratio i 347.62

PEG Ratio i -252.45

Div. Yield i 0.00%

ROE i -414.62%

Beta i 0.211

Debt to Equity i 2,358.26

Financial Highlights

Profitability

Gross Margin i 88.04%

Operating Margin i 3.04%

Profit Margin i -11.49%

Returns and Earnings

Return on Assets (TTM) i -1.79%

Return on Equity (TTM) i -414.62%

EBITDA i $-57.8M

Net Income (TTM) i $-269.7M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Alnylam ALNY	40.16B Large-cap	2.38%	15.41%	27.40%	25.48%	31.83%	92.03%	124.66%	104.36%
Vertex VRTX	116.96B Large-cap	1.10%	5.43%	-9.44%	-1.79%	12.25%	-5.26%	73.12%	55.30%
Regeneron REGN	57.14B Large-cap	7.30%	-7.82%	-22.24%	-27.63%	-26.00%	-48.94%	-8.90%	-17.81%
Royalty Pharma plc RPRX	19.59B Large-cap	3.14%	6.15%	6.61%	40.26%	35.09%	29.42%	-11.46%	-28.90%
Insmed INSM	17.98B Large-cap	34.11%	50.25%	31.52%	37.83%	41.14%	54.46%	431.38%	241.39%
Incyte INCY	13.11B Large-cap	-1.48%	11.41%	0.06%	-1.17%	-2.56%	9.08%	-4.94%	-35.72%

Ownership & Short Interest

Insider Ownership i 3.83%

Institutional Ownership i 97.50%

Shares Short i 3M

Short Ratio i 3.18

Short % of Shares Outstanding i 3.49%

Average 10-Day Volume i 740K

Average 90-Day Volume i 959K

Alnylam Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Alnylam would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is ALNY's 52-week high and low?

In the last 52 weeks, Alnylam reached a high of $310.22 (on June 6, 2025) and a low of $152.30 (on June 18, 2024).

What is the market cap and P/E ratio for ALNY?

Curious about Alnylam's size and valuation? Its market capitalization stands at 40.16B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -252.45.

Does ALNY pay dividends? If so, what's the yield?

As for dividends, Alnylam isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Alnylam's main competitors or similar companies to consider before investing?

When looking at Alnylam, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	116.96B	Healthcare	Biotechnology	-5.26%	73.12%
Regeneron REGN	57.14B	Healthcare	Biotechnology	-48.94%	-8.90%
Royalty Pharma plc RPRX	19.59B	Healthcare	Biotechnology	29.42%	-11.46%
Insmed INSM	17.98B	Healthcare	Biotechnology	54.46%	431.38%
Incyte INCY	13.11B	Healthcare	Biotechnology	9.08%	-4.94%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Alnylam Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Alnylam's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -414.62%, the Debt to Equity ratio from the most recent quarter is 2,358.26, and its Gross Profit Margin stands at 88.04%.

What is the recent revenue and earnings growth for ALNY?

Looking at Alnylam's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 20.20%, and quarterly earnings saw a YoY growth of 20.20%.

How much of ALNY stock is held by insiders and institutions?

Wondering who owns Alnylam stock? Company insiders (like executives and directors) hold about 3.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.50%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.